Related Experiment Video
Updated: Aug 15, 2026
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
[Recommendations for the prevention of respiratory syncytial virus infection]
J Figueras Aloy1, J Quero, E Doménech
1Hospital Clínic, Institut Clínic de Ginecología, Obstetricia y Neonatología, Universitat de Barcelona, Spain. jfiguer@clinic.ub.es
Insights
High-risk infants, including premature babies and those with congenital heart disease, benefit from palivizumab (RSV monoclonal antibodies) to reduce respiratory syncytial virus (RSV) hospitalizations. Guidelines detail strong recommendations and conditional use based on gestational age and risk factors.
Area of Science:
- Pediatrics
- Infectious Diseases
- Neonatology
Context:
- Respiratory Syncytial Virus (RSV) poses a significant threat to vulnerable infant populations.
- Premature infants and those with congenital heart disease are at high risk for severe RSV infection and hospitalization.
- Current preventative strategies include hygienic measures and palivizumab prophylaxis.
Purpose:
- To outline current guidelines for the administration of palivizumab for RSV prevention in high-risk infants.
- To identify specific criteria for strongly recommended and recommended use of palivizumab.
- To inform clinical practice regarding RSV prophylaxis in at-risk neonates and infants.
Summary:
- Infants born at or before 35 weeks gestation, with or without chronic lung disease (CLD), and those with severe congenital heart disease are considered high-risk for RSV infection.
- Palivizumab (RSV monoclonal antibodies) is recommended for premature infants (≤28 weeks gestation or 29-32 weeks with specific conditions) and those with CLD or severe congenital heart disease.
- Conditional recommendations for palivizumab exist for infants 32-35 weeks gestation with multiple risk factors, including age, breastfeeding status, and household/environmental factors.
Impact:
- Reduced rates of RSV hospitalization in high-risk infant populations.
- Improved clinical outcomes and decreased healthcare burden associated with severe RSV infections.
- Standardized approach to palivizumab prophylaxis, ensuring optimal use in eligible infants.
Abstract:
Premature babies < or = 35 weeks gestation, with or without chronic lung disease (CLD), and infants affected by severe congenital heart disease should be considered high risk population for RSV infection and hospitalization. Hygienic measures and RSV monoclonal antibodies (palivizumab) have been found useful in decreasing rates of RSV hospitalization in these patients. Guidelines for their administration include: a) strongly recommended use in premature babies < or = 28 weeks gestation, or born between 29-32 weeks gestation and less than 6 months at start of RSV station or discharged along it, or affected by CLD in treatment during last 6 months or by severe congenital heart disease. Last two groups could be prophylaxed for two RSV seasons. b) Recommended use among premature babies between 32-35 weeks gestation and less than 6 months of age and presenting two or more risk factors: chronologic age < 10 weeks at start of RSV station, breastfeeding < or = 2 months (physician prescription), sibling < 14 years old, day-care assistance, family history of wheezing, > or = 4 adults at home, airways malformation or neuromuscular disease.
More Related Videos
Related Concept Videos
01:29Respiratory Syncytial Virus Disease
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:17Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...